Nootropic
Dihexa
THERE IS ESSENTIALLY NO HUMAN DATA ON DIHEXA.
Also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408 · Angiotensin IV analogue
NO HUMAN DATA
No human trial has ever been published for this compound. The dose, the frequency and the cycle length on this page describe what unregulated users report doing. They are not findings.
Never completed a published human trial. No human pharmacokinetics, no human toxicology, no approved product anywhere.
At a glance
Dose summary
No reliable human half-life has been published for Dihexa, so none is listed rather than guessed at.
No regulator and no trial set these numbers. They describe what people actually do, recorded so you can see the range rather than guess at it — which is not the same thing as a recommendation.
Form
Nothing to reconstitute
Dihexa is taken by mouth, not injected, so there is no vial, no diluent and no draw volume. The typical dose is 5 mg per administration — that is the number on the capsule or tablet, and the reconstitution calculator deliberately excludes this compound.
Mechanism & evidence
What it is, and what is known
THERE IS ESSENTIALLY NO HUMAN DATA ON DIHEXA. It is a small-molecule angiotensin IV analogue developed in an academic laboratory (Washington State University) that potentiates hepatocyte growth factor signaling at its receptor c-Met and promotes synaptogenesis. Every efficacy claim attached to it comes from rodent work: scopolamine-impaired and lesioned rats, and Parkinson and Alzheimer disease models. It has never completed a published human trial, there is no published human pharmacokinetic or toxicology data, and no approved product exists anywhere.
Because of that, the range given here is deliberately narrow and conservative: it is derived from what unregulated users report taking (roughly 3-20 mg per day orally or transdermally), NOT from any dose-finding study, and it should be read as a description of practice, not a recommendation. The active-malignancy flag is not a formality: c-Met is a well-characterized oncogenic pathway and chronically potentiating it in a person with an existing or suspected cancer is a real theoretical hazard.
It is taken as a powder or in a carrier rather than reconstituted for injection, so the vial and bacteriostatic water fields do not apply in the usual way.
Tolerability
Reported side effects
- No human side-effect profile exists; nothing below is established
- Headache reported anecdotally
- Overstimulation or disturbed sleep reported anecdotally
- Skin irritation when applied topically in a DMSO carrier
- Theoretical tumor-promotion risk through HGF/c-Met signaling
Hard stops
Do not use this if
- Pregnancy, possible pregnancy, or breastfeeding
- Active, suspected or recently treated malignancy
- Under 18
These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.
Handling
Storage
Keep it cold, dry and dark. The figures above are shelf-life conventions, not stability testing on the product you bought.
Combinations
Commonly stacked with
Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.
References
Sources
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.